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Pregnancy in opioid-dependent women is a major public health issue. Women who are aﬄicted by opioid addiction are a highly
vulnerable group of patients frequently becoming pregnant unplanned and at risk of adverse pregnancy outcomes and peri-
natal complications. Opioid agonist maintenance treatment is the best option for the majority of women. Ideally, early and
closely monitored treatment in an interdisciplinary team approach including social workers, nurses, psychologists, psychiatrists,
gynecologists, anesthesiologists, and pediatricians should be provided. The treatment of comorbid psychiatric conditions, the
resolution of ﬁnancial, legal, and housing issues, and the psychosocial support provided have a signiﬁcant eﬀect on optimizing
pregnancy outcomes. This paper aims to update health professionals in the ﬁeld of gynecology and obstetrics on the latest optimal
treatment approaches for mothers suﬀering from opioid dependence and their neonates.
1.Introduction
Illicit drug use among pregnant women is an international
health issue that has become of increasing relevance in
the past decades. In 2001, a national household survey
reported 3.7% of pregnant women in the United States
using illicit drugs [1]. In 2009 this number had increased
to 4.5% [2]. The actual numbers are higher if estimated
numbers of unreported cases are taken into account due to
fear of stigmatism impairing self-report measures. In fact, a
study of maternal urine samples at delivery of 715 women
in Florida showed 13.3% were positive for an illicit drug
such as marijuana, cocaine, or opiates. Although among
illicit substances, the prevalence of substance abuse among
pregnant women was highest for marijuana, followed by
cocaine [3], the prevalence of opioid dependence was on
the rise between 1970 and 1980 [4]a n da ne s t i m a t e d8
million people worldwide were reported to abuse opioids
in 2003 [5]. Though men still outnumber women, the
proportion of women continues to increase, and more
than 70% of opioid-dependent women are of child-bearing
age. Unplanned pregnancies are common due to eﬀects
of opioids on the female reproductive system, frequently
leading to irregular menstruation or amenorrhea [6]. Addi-
tionally, chaotic lifestyles associated with drug abuse often
foster insuﬃcient birth control measures and consequently
unexpected pregnancies. In fact, the rate of unintended
pregnancies has been found to range between 80% and 90%
among opioid-dependent women [7].
2. Opioid Dependence andPregnancy
Opioid-dependent women commonly face numerous
socioeconomicproblemssuchasunemployment,coaddicted
partners, and partner violence [8]. Prostitution as a means
of attaining drugs often leads to health problems such as
infectious disease or these occur as a consequence of syringe
sharing and are poorly attended to [9]. The majority of
opioid-dependent women suﬀer cooccurring psychiatric
disorders with prevalence numbers ranging between 56
and 73%, mainly aﬀective disorders, PTSD, or personality
disorders [9–11] (see Table 1).
The failure to recognize mental disorders is a major risk
to the health of mother and neonate as comorbid depression,
anxiety disorders, and psychosis are associated with a variety2 Obstetrics and Gynecology International
Table 1: Psychiatric comorbidity in substance abuse treatment and
matched controls∗.
SA Controls
Depression 36.3% 4.2%
Anxiety disorder 16.3% 2.3%
ADHD 17.2% 3.0%
Conduct disorder 19.3% 1.2%
Conduct disorder (w/ODD) 27.3% 2.3%
Any psychiatric diagnosis 55.5% 9.0%
∗All P<. 001 [12].
of negative pregnancy outcomes [13]. Examples of these are
preterm labor and poor fetal growth [14, 15], a heightened
risk for perinatal complications and dysfunctional mother-
child bonding [16]. Ideally, comorbid psychiatric conditions
should be adequately treated, and the use of antidepressant
drugs such as SSRI medication, which has been shown to
be safe during pregnancy, may be indicated. However, a
careful risk-beneﬁt evaluation of pharmacological treatment
byapsychiatricprofessionalexperiencedintreatingpregnant
women is warranted [17]. It should be part of a multipro-
fessional team approach comprising psychiatrists, psychol-
ogists, gynecologists, midwifes, nurses, social workers, and
anesthesiologists. (see Figure 1).
3. Medical Treatment of Opioid-Dependent
PregnantWomen
Though ultimately, abstinence from opioids might seem the
best option during pregnancy, few opioid-addicted women
can handle abstaining from opioids at such a time in
their lives ﬁlled with changes and stress. Additionally, rapid
detoxiﬁcation during pregnancy cannot be recommended
from a medical standpoint, as withdrawal has been linked
to intrauterine stress for the fetus associated with poor
fetal growth, preterm delivery, and fetal death [18]. Though
gradual detoxiﬁcation in the second or third trimesters
has been achieved in a selected group of women, the
majority of women have a high risk of relapse. The best
option for most opioid-addicted pregnant women is opioid
maintenance treatment with a long-acting synthetic opioid
such as methadone or buprenorphine [19–24]. Methadone
has for a long time been the established maintenance
medication for pregnancy [25, 26], however, in recent years,
buprenorphine has been increasingly subject of studies as a
valuable alternative to methadone with beneﬁcial eﬀects on
the neonatal abstinence syndrome of the newborn.
Pioneer work with standardized prospective evaluation
on the use of buprenorphine in pregnant women has
been conducted in the late 1990s by Fischer et al. at
the Addiction Clinic in Vienna, who was ﬁrst to pub-
lish a study demonstrating maternal and fetal safety of
women maintained on buprenorphine during pregnancy
and consecutively during conception [22, 27]. The pilot
study published in 2000 was followed by a double-blind,
double dummy comparison study of 14 women published
in 2006, forming a ﬁrst basis for larger follow-up studies
and showing higher retention rates in the buprenorphine
group. So far, the largest double-blind, double dummy
study comparing the safety and eﬃcacy of buprenorphine
versus methadone in pregnant opioid-dependent women
was the “MOTHER study” (Maternal Opioid Treatment:
Human Experimental Research). It was conducted between
2005 and 2008 as a multisite randomized controlled trial
encompassing 6 US American sites and one European site at
the Addiction Clinic, University Hospital of Vienna, Austria.
The main outcome of this trial of 131 completers and
their neonates was recently published in the New England
Journal of Medicine [28], ﬁnding that neonates prena-
tally exposed to buprenorphine had a signiﬁcantly shorter
duration of treatment and required signiﬁcantly lower
amounts of morphine medication compared to methadone-
exposed neonates. The shorter duration of hospitalization of
buprenorphine-exposed neonates should also be seen in the
light of health service costs, as large numbers of neonates
are aﬀe c t e db yN A Se v e r yy e a r .H o w e v e r ,t r e a t m e n tw i t h
methadone still has its place as 28 of 86 women in the
buprenorphine group (33%) discontinued treatment com-
pared to 16 of 89 women (18%) maintained on methadone
[28] .B u p r e n o r p h i n ec a nb es e e na sa ni m p o r t a n tt r e a t m e n t
option for this target group, but methadone continues to
be the medication for those women who do not positively
respond to buprenorphine.
Another important aspect aﬀecting pregnant opioid-
maintained women that deserves mention is the need
for dose adjustment in the majority of women, usually
around the beginning of the third trimester, due to changes
in metabolic rates, increased estrogen levels, and enzyme
induction [29, 30]. After delivery, most women will request
dose decreases due to changes in hormonal status. The same
principle applies to the use of psychotropic medications
during pregnancy, such as SSRIs, where frequently dose
adjustment is necessary, and psychiatric symptoms can
worsen temporarily.
Recentreportshaveshownthatnotonlythedosebutalso
the duration of maintenance treatment during pregnancy
plays a role in improvement of pregnancy outcomes, as in
a recent study women who had been on methadone mainte-
nance treatment (MMT) for the full pregnancy had higher
birth weights and a higher likelihood of abstinence from
concomitant medication associated with higher gestational
age at delivery compared to women who had only been on
MMT for part of their pregnancy [31]. Results from studies
like this emphasize the responsibility of gynecologists to
seek close cooperation with addiction specialists as soon as
pregnancy is ascertained.
4. PerinatalPain Management of
Opioid-Dependent Women
Opioid dependence is associated with heightened sensitivity
to pain, chronic hyperalgesia, and tolerance to opioid pain
medication [32], making peripartum pain management of
opioid-dependentwomenparticularlychallenging.ThereisaObstetrics and Gynecology International 3
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Figure 1: The multiprofessional team approach at the Addiction Clinic, University hospital of Vienna, Department of Psychiatry.
persistent lack of standardized treatment recommendations,
stigma, and overcaution due to fear of “drug-seeking”
behavior, resulting in undertreatment of peripartum pain
in the majority of cases. Additional factors such as nicotine
addiction also contribute to heightened pain sensitivity [33,
34]. This is signiﬁcant given that more than 90% of opioid-
dependent women are smokers [35]. Due to abrupt nicotine
deprivation in the hospital, they often require higher doses
of pain medication [36]. Furthermore, the high prevalence
of other psychiatric diagnoses, such as aﬀective disorders,
represent an additional independent predictor of intensiﬁed
pain experience [32, 37]. Prior recommendations on pain
treatment of opioid-dependent patients have stressed the
importance of continuous, adequately dosed maintenance
treatment as a basis [38]. Recent ﬁndings support this
recommendation and, additionally, the use of NSAIDs
(NonSteroidal Anti-Inﬂammatory Drugs) to supplement,
and the use of opioids, other than the ones used for
maintenance treatment, for suﬃcient pain control during
delivery and postpartum [32, 39]. The use of NSAIDs cannot
be recommended during pregnancy, particularly during the
third trimester due to the risk of early closure of the ductus
arteriosus. In early pregnancy the use of NSAIDs has been
linked to increased risk of miscarriage and premature birth
[40].
5. The Neonatal Abstinence Syndrome of
the Newborn
The neonatal abstinence syndrome of the newborn is a
condition which becomes manifest in the ﬁrst few days
after delivery aﬀe c t i n gm o r et h a nh a l fo fn e w b o r n sb o r n
to opioid-dependent mothers [41]. It is characterized by
symptoms aﬀecting primarily the central nervous system,
the respiratory system, and the digestive tract. The ﬁrst
scale for measurement of neonatal abstinence syndrome was
developed by Loretta Finnegan et al. in the early 1970s [42].
It consists of symptoms such as increased sneezing, watery
eyes,frequentyawning,poorsucking,reducedsleepduration
after feeding, and increased (hyper) reﬂexes. Management
of this condition is best handled in a multiprofessional
team approach in specially trained centers, where symptoms
of neonates are rated at regular intervals and, if needed,
treatment is initiated using morphine hydrochloride drops
giventoinfants.In2007,FischerandcolleaguesattheVienna
addiction clinic published a study comparing phenobarbital
to morphine hydrochloride as NAS treatment medication,
showing that the majority of neonates had a signiﬁcantly
shorter duration of NAS under morphine hydrochloride
drops which has become the established form of treatment
[43]. However, prolonged use of morphine in the postnatal
period should be avoided as recent studies have demon-
strated a number of negative consequences of opioids on
neural cells of the growing brain [44].
A recently updated Cochrane review by Osborn referring
to treatment options in 645 infants conﬁrmed that opiate
(morphine) treatment is superior to supportive care only.
The analysis of prior studies also showed that opiate treat-
ment was also superior to phenobarbitone and to diazepam
in terms of rates of treatment failure and in reducing the
likelihood of seizures [41]. The basis for eﬀective medical
treatment of NAS is the standardized rating of symptoms in
neonates and supportive nonpharmacological interventions
[45].
6. IndividualPredispositionto NAS
A question which has not been resolved despite numerous
hypotheses is why some neonates will develop symptoms
of neonatal abstinence syndrome, and others will not. The4 Obstetrics and Gynecology International
majority of studies that have examined the association
between maternal maintenance dose and NAS have found
no association [21, 23, 27, 46–50] .Am o s tr e c e n tr e v i e w
and meta-analysis of 67 studies on maternal methadone dose
and NAS, and another encompassing 10 studies with various
medications, support prior ﬁndings, also not reporting any
correlation [51, 52]. Factors that do have an impact on NAS
and neonatal outcomes are concomitant consumption of
opioids, cocaine, or other substances. In particular, benzo-
diazepine consumption has been associated with prolonged
neonatal abstinence syndromes [53]. Another factor, which
has been shown to play an important role during pregnancy,
is the use of nicotine, as over 90% of opioid-dependent
pregnant women are strongly dependent on nicotine [35,
54]. The prescription use of SSRIs and other psychotropic
medicationsalsohasanegativeimpactonNAS[55].Therole
of neonatal gender in NAS occurrence has been addressed
in two prior studies which found inconclusive results. One
study of a population of 64 neonates exposed to methadone
found that male neonates exhibited a higher NAS intensity
in the ﬁrst four days postpartum, however, no sex-speciﬁc
diﬀerences in rates of NAS treatment were found [55]. The
second study reported no signiﬁcant sex-related diﬀerences
in a retrospective chart review of 308 methadone-exposed
neonates [56].
Though some factors have been determined that can be
seen as predictors of NAS, a lot of questions around this
topicremainunresolved.Thereisagoodchancethatanswers
may actually rather be found on a more complex level such
as biochemical processes in the placenta. Genetic variations
of certain placental transporter genes could explain levels of
maternal opioids in the fetal circulation during pregnancy,
which in turn could explain severity and incidence of NAS
[57, 58]. However, further research is needed to clarify these
ﬁndings,anditisalsoquestionablehowsuchgeneticﬁndings
can contribute to therapeutic options.
7.BreastfeedingandMaintenanceTreatment
Breastfeeding under oral opioid agonist treatment is
recommendable for women if they are not comorbidly
suﬀering from active forms of infectious disease such as
hepatitis C with high blood viral loads; HIV is a deﬁnite
contraindication. For methadone, breastfeeding can reduce
the severity and duration of NAS and delay the onset
of symptoms [59–61]. One reason for this can be the
comfort obtained through mother/child bonding, another,
the oral bioavailability of methadone. As a result of breast
feedingundermethadonemaintenance,theneedformedical
treatment of NAS may be decreased [61]. If women want to
breastfeed and no contraindication such as either infectious
disease or continued illicit drug use exists, physicians should
support their needs [62–64]. The safety of buprenorphine
in breastfeeding has not been well-investigated. So far, data
available show low concentrations in breast milk [65] so that
a similar recommendation might be valid as for methadone.
Nonetheless, though ﬁndings so far are supportive, they
are restricted by shorter periods of observation and smaller
numbers of investigated cases [66].
8. Conclusion
Opioid-dependent pregnant women are a highly vulnerable
group of patients who frequently have unplanned pregnancy
[7] and are at risk of unfavorable outcome and peri-
natal complications. They often suﬀer comorbid psychiatric
disorders that need to be recognized and treated adequately
in order to avoid complications during pregnancy and
ensure a chance for healthy mother-child interaction. The
majority of women beneﬁts most from opioid agonist
maintenance therapy with a long-acting synthetic opioid
such as methadone or buprenorphine. The management
of pain during delivery and thereafter is often challenging
due to opioid tolerance and heightened pain sensitivity.
Opioid-dependent pregnant women are in need of early
and closely monitored treatment in a multiprofessional team
approach including social workers, nurses, psychologists,
psychiatrists, gynecologists, anesthesiologists, and pediatri-
cians. The resolution of ﬁnancial, legal, and housing issues,
and the psychosocial support provided through treatment
have a signiﬁcant eﬀect on optimizing pregnancy outcomes.
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